In-Vitro Lung Model Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 17.30 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
In-Vitro Lung Model Market Analysis
The In Vitro Lung Model market is expected to register a CAGR of nearly 17.3% during the forecast period.
The COVID-19 virus has spread across the world and its lethality had put scientists and pharmaceutical companies worldwide on the spot to develop novel treatment options and reliable vaccination for billions of people. To combat its associated disease COVID-19 and potentially newly emerging coronaviruses, numerous pre-clinical cell culture techniques were initiated. The COVID-19 pandemic had a significant impact on the in-vitro lung model market. For instance, an article titled, "In Vitro Lung Models and Their Application to Study SARS-CoV-2 Pathogenesis and Disease" published in April 2021 reported that the pandemic had a significant impact on the in-vitro lung model as the spread of SARS-CoV-2 led to the development of in-vitro lung model to study the pathogenesis of this virus. Initially, the growth of this market was hampered by strict lockdowns, as lockdowns led to certain restrictions and scarcity of many goods but with the increase in clinical studies and understanding of the pathophysiology of this virus, the studied market witnessed significant growth.
The factors that are driving this market are the growing focus on developing alternatives for animal testing models technological advancements and the development of new 3D in vitro models. Due to the ethical issues associated with animals, and, despite large similarities, their differences between a given animal species and humans, scientists and researchers have led to the development of an in-vitro model. Also, the increase in the number of pathogens that cause respiratory disease is leading to the development of lung models to understand the pathogenesis of the microbes. For instance, an article titled 'Advanced In Vitro Lung Models for Drug and Toxicity Screening: The Promising Role of Induced Pluripotent Stem Cells' published in December 2021 reported that induced pluripotent stem cells (iPSCs) and organ-on-chip (OOC) technologies possess suitable characteristics for the generation of physiologically relevant in vitro lung models, allowing for developmental studies, disease modeling, and toxicological screening.
Similarly, another article titled, "3D Lung-on-Chip Model Based on Biomimetically Microcurved Culture Membranes" published in May 2022 reported that the complexity of the pulmonary architecture and microenvironment, the inaccessibility of primary lung cells, and the difficulty in maintaining the cellular identity and specific phenotype in vitro have hindered the development of suitable platforms for basic and developmental lung research, disease modeling, and pharmacological screening. All these issues have been overcome by in vitro modeling, which has effectively counteracted the disadvantages of other commonly used cellular sources. Thus, these technological advancements are leading to the development of alternative animal testing models.
The advancements and the development of new 3D in vitro models also have driven the growth of this segment. For instance, an article titled, "Human pluripotent stem cell-derived lung organoids: Potential applications in development and disease modeling" was published in November 2020 and reported that the development of 2D in vitro systems and animal models have been largely employed to elucidate the molecular mechanisms underlying human lung development, physiology, and pathogenesis. More recently, human-derived three-dimensional (3D) models have been generated allowing for a deeper understanding of cell-to-cell communication. The advent of human pluripotent stem cells (hPSCs) and 2D) and three-dimensional (3D) cultures have proven to be reliable models for studying lung development and exploring lung disease pathogenesis and underlying mechanisms.
Thus, due to the aforesaid mentioned reasons, the market is expected to witness significant growth over the forecast period. However, a dearth of skilled professionals may slow down its growth over the forecast period.
In-Vitro Lung Model Market Trends
This section covers the major market trends shaping the In-Vitro Lung Model Market according to our research experts:
2D Cell Models Segment is Expected to Witness Significant Growth Over the Forecast Period.
2D cell culture systems grow cells on flat dishes, typically made of plastic. The cells are put onto coated surfaces where they adhere and spread. The 2D cell cultures are mostly used as they are less expensive, well established, easier cell observation and measurement, and lots of literature are available on them. The 2D cell culture models are used in drug discovery and toxicology, 3D model development, and basic research. The other factors driving the segment growth are, increasing awareness and focus on developing alternatives for animal testing models and increasing investments and funding for product development and research.
In the last few decades, there has been an effort to develop in vitro lung models to study and understand the mechanism of various lung diseases, such as chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), and cystic fibrosis (CF). The cases of these diseases lead to the development 2-D lung model to understand the pathogenesis of these microbes. For instance, in 2021, the Centre for Disease Control and Prevention (CDC) reported that in 2020 globally, 21,030,479 adult cases and 4,226,659 children were reported to suffer from asthma. Thus, rising cases of these diseases are boosting the development of a 2-D lung model to understand the pathogenesis of this disease, thereby driving the growth of the segment.
The development of new therapeutics for the treatment of rising lung diseases requires advanced organ models that closely recapitulate the complexity of the human lung. Complementary in vitro, ex vivo, and in vivo animal models have been developed to study and understand various pulmonary diseases. In vitro models (2D cell culture) using epithelial cell lines are high-throughput and robust but are limited by their reliance on cell lines originating from cancer tissue or that have been immortalized.
For instance, an article titled, 'A Robust Protocol for Decellularized Human Lung Bioink Generation Amenable to 2D and 3D Lung Cell Culture' published in June 2021, reported that human lung tissues have been decellularized and enzymatically solubilized to form a bioink that can be used for 2D and 3D cell culture applications. Moreover, the results from this mentioned study indicated that the decellularized extracellular matrix(dECM) solution could be used to coat transwell inserts to enhance cell adhesion and growth. Such decellularized extracellular matrix (dECM) based bioink could potentially be utilized to fabricate in vitro lung constructs for modeling and studying various pulmonary diseases in the future.
Thus, due to the aforesaid-mentioned reasons, the segment is expected to witness significant growth over the forecast period.
North America Region is Expected to Witness Significant Growth Over the Forecast Period.
North America is expected to dominate the overall market, throughout the forecast period. The market growth is due to factors such as the presence of key players, increasing animal welfare programs and regulations, and established healthcare infrastructure. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase the market growth. Also, due to supportive healthcare policies, high investments for product development, strict regulations and acts regarding animal welfare and increasing programs and campaigns for their support, and a developed healthcare market.
The growing research on lung diseases is projected to offer growth potential for the in vitro lung model market in the region. The cases of asthma, lung cancer, and COPD have been rising across the globe at a significant speed. For instance, International Agency for Research on Cancer, GLOBOCAN database 2020 reported that the North American region in 2020 reported to have 254 thousand lung cancer cases and this number is expected to increase by 352 thousand by 2040. Thus, a high number of lung cancer cases is boosting the market for lung models to understand the better pathogenesis of this disease, thereby will lead to better cure and treatment of this disease.
Also, recent developments, partnerships, mergers ad acquisitions in the region are fueling the growth of the studied market in the region, For instance, in December 2021, Lonza Group AG and Agilent Technologies promulgated the strategic collaboration to integrate new analytical technologies with Lonza's Cocoon Platform. The collaboration aims to develop and integrate current and new analytical technologies into patient-scale cell therapy manufacturing workflows with the Cocoon Platform. This collaboration brings both companies a step closer to their commitment to developing sustainable technologies and solutions that increase access to life-saving cell-based therapies for various lung diseases.
Similarly, in September 2021, BICO subsidiaries CELLINK, MatTek, and Visikol promulgated the launch of a collaboration combining the expertise of the three companies to establish a contract research organization (CRO) with comprehensive bioprinting services. By forming a joint contract research organization (CRO), CELLINK, MatTek and Visikol have granted their customers access to offerings from all three companies. The partnership furthers the BICO groups' commitment to its Bio Convergence agenda by identifying synergies in the bioprinting business area to offer customers solutions trending toward the future of health. Thus, due to the aforesaid-mentioned reasons the region is expected to witness significant growth over the forecast period.
In-Vitro Lung Model Industry Overview
The in vitro lung model market is moderately competative and consists of a few major players. Some of the companies which are currently dominating the market are Epithelix Sarl, Mattek Corporation, Emulate, AlveoliX AG, ATCC Global, Mimetas Us, Inc., Tissuse GmbH, Insphero AG, Cn Bio Innovations Limited, and Lonza Group AG.
In-Vitro Lung Model Market Leaders
-
Epithelix Sarl
-
Mattek Corporation
-
AlveoliX AG
-
ATCC Global
-
Tissuse GmbH
*Disclaimer: Major Players sorted in no particular order
In-Vitro Lung Model Market News
- In September 2022, Merit Medical Systems launched TEMNO Elite Soft Tissue Biopsy System. It is indicated for use in various soft tissue locations such as liver, lung, lymph nodes, kidney, and other soft tissue suspect lesions.
- In May 2022, AlveoliX entered a partnership with InSCREENeX. Through this partnership, InSCREENeX's cutting-edge CI-SCREEN methodology with AlveoliX's patented organ-on-chip technology will develop a new immortalized alveolar cell line, specially tuned for on-chip applications.
In-Vitro Lung Model Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Growing Focus on Developing Alternatives for Animal Testing Models
- 4.2.2 Technological Advancements and the Development of New 3D In Vitro Models
-
4.3 Market Restraints
- 4.3.1 Dearth of Skilled Professionals
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Type
- 5.1.1 2D Cell Models
- 5.1.2 3D Cell Models
-
5.2 By Application
- 5.2.1 Drug Screening
- 5.2.2 Toxicology
- 5.2.3 Others
-
5.3 Geography
- 5.3.1 North America
- 5.3.1.1 United States
- 5.3.1.2 Canada
- 5.3.1.3 Mexico
- 5.3.2 Europe
- 5.3.2.1 Germany
- 5.3.2.2 United Kingdom
- 5.3.2.3 France
- 5.3.2.4 Italy
- 5.3.2.5 Spain
- 5.3.2.6 Rest of Europe
- 5.3.3 Asia-Pacific
- 5.3.3.1 China
- 5.3.3.2 Japan
- 5.3.3.3 India
- 5.3.3.4 Australia
- 5.3.3.5 South Korea
- 5.3.3.6 Rest of Asia-Pacific
- 5.3.4 Middle East and Africa
- 5.3.4.1 GCC
- 5.3.4.2 South Africa
- 5.3.4.3 Rest of Middle East and Africa
- 5.3.5 South America
- 5.3.5.1 Brazil
- 5.3.5.2 Argentina
- 5.3.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Epithelix Sarl
- 6.1.2 Mattek Corporation
- 6.1.3 Emulate
- 6.1.4 AlveoliX AG
- 6.1.5 ATCC Global
- 6.1.6 Mimetas Us, Inc.
- 6.1.7 Tissuse GmbH
- 6.1.8 Insphero AG
- 6.1.9 Cn Bio Innovations Limited
- 6.1.10 Lonza Group AG
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityIn-Vitro Lung Model Industry Segmentation
As per the scope of the report, in vitro lung models are defined as cell models that represent normal or diseased lung physiology. These cells when constructed in a monolayer on a Petri plate are called 2D in vitro models. 3D models have a 3-dimensional architecture and use supports and scaffolds to maintain their structure. The in vitro lung model market is segmented by Type (2D Cell Models, 3D Cell Models), Application (Drug Screening, Toxicology, and Other Applications), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments.
| By Type | 2D Cell Models | |
| 3D Cell Models | ||
| By Application | Drug Screening | |
| Toxicology | ||
| Others | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
In-Vitro Lung Model Market Research FAQs
What is the current Global In Vitro Lung Model Market size?
The Global In Vitro Lung Model Market is projected to register a CAGR of 17.30% during the forecast period (2024-2029)
Who are the key players in Global In Vitro Lung Model Market?
Epithelix Sarl, Mattek Corporation, AlveoliX AG, ATCC Global and Tissuse GmbH are the major companies operating in the Global In Vitro Lung Model Market.
Which is the fastest growing region in Global In Vitro Lung Model Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global In Vitro Lung Model Market?
In 2024, the North America accounts for the largest market share in Global In Vitro Lung Model Market.
What years does this Global In Vitro Lung Model Market cover?
The report covers the Global In Vitro Lung Model Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global In Vitro Lung Model Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global In Vitro Lung Model Industry Report
Statistics for the 2024 Global In Vitro Lung Model market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global In Vitro Lung Model analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
